Advisory Committee Briefing: How to Build the Dossier, Orchestrate the Story, and Master the Q&A Winning Your FDA Advisory Committee: Briefing Materials, Storyline, and Live Q&A Readiness What an FDA Advisory Committee Is—and Why It Shapes First-Cycle Outcomes An FDA Advisory Committee (AdComm) is a public, expert panel convened by the Agency to provide independent advice on whether a drug’s benefits outweigh its risks for a defined use. The committee’s vote is non-binding, but it frequently signals the direction of the final decision and often determines the tenor of labeling and post-marketing obligations. An AdComm creates three unusual pressures for…

Dossier Gap Analysis: Objective, Scope, and US/EU Review Criteria for a Submission-Ready CTD Running a CTD Dossier Gap Analysis: Purpose, Boundaries, and Reviewer-Centric Criteria Why Perform a Dossier Gap Analysis: Triggers, Outcomes, and What “Good” Looks Like A dossier gap analysis is a structured, time-boxed review of draft CTD/eCTD content to identify what is missing, misaligned, or unverifiable before a formal submission or major supplement. Sponsors typically trigger it at key milestones—end of Phase 3 (to confirm evidence completeness), pre-NDA/BLA/ANDA (to lock narratives and anchors), or pre-variation (to confirm lifecycle coherence). The analysis is not a general editorial pass; it…

Finding Incomplete or Inconsistent CTD Content: Practical Patterns, Spot-Checks, and Fix Plans How to Detect and Fix Incomplete or Inconsistent CTD Content—With Real Examples Where Incompleteness Hides: A Reviewer’s Map of High-Risk CTD Locations Incomplete or inconsistent content is rarely random—it clusters in predictable places where science meets formatting and handoffs. Start with the QOS (2.3), which many teams treat as an abstract. In reality it’s a claims ledger that reviewers read first and then chase into Modules 3–5. If your QOS cites an assay acceptance range, a PPQ capability, or a stability-derived shelf-life, those numbers must be verifiable in…

Legacy Dossiers to Current Standards: Update Paths, Risk Priorities, and a Practical Modernization Playbook Modernizing Legacy Dossiers: How to Prioritize Risks and Upgrade Content to Today’s Standards What Counts as a “Legacy Dossier” and Why It Creates Regulatory Risk “Legacy” doesn’t just mean old— it means out of sync with the expectations reviewers apply today. Typical signs include: Module 2 summaries that don’t map cleanly to supporting anchors; Module 3 quality sections written before contemporary control-strategy thinking (e.g., Established Conditions and lifecycle verification); nonclinical reports without explicit GLP/QAU attestations or exposure margins; CSRs drafted prior to modern estimand language and…

Common Labeling & Clinical Summary Gaps: SPL/PI Pitfalls and How to Prevent Them Labeling–Summary Mismatches: The SPL/PI Pitfalls That Slow Reviews—and How to Avoid Them Why Labeling and Clinical Summaries Drift Apart: Root Causes and Reviewer Signals Labeling errors rarely originate in the label. They begin upstream when numbers, definitions, and qualifiers diverge between clinical study reports (CSRs), integrated summaries (ISS/ISE), and Module 2 narratives—and then reach the Prescribing Information (PI) through hurried copy-and-paste or late edits. The result is a dossier that says three subtly different things about the same endpoint: one in the CSR table, another in the…

Internal vs External Dossier Audits: When to Choose Each, How to Scope Them, and What “Approval-Ready” Looks Like Choosing Between In-House and Third-Party Dossier Audits: Scenarios, Scope, and Evidence-Ready Outputs What a Dossier Audit Is (and Isn’t): Purpose, Depth Options, and Decision-Focused Deliverables A dossier audit is a structured, time-boxed examination of draft or live submission content to determine whether your CTD/eCTD is complete, consistent, verifiable, and navigable from a regulator’s point of view. It is not a line-edit, a peer review, or a scientific debate; it is a reviewer simulation that asks whether a claim in Module 2 can…